- Advanced or metastatic HER2-overexpressing breast cancer:
- PO 1250mg OD on Days 1-21 continuously in combination with capecitabine (PO 2000mg/m²/day divided BD) on Days 1-14 in a repeating 21-day cycle
- For patients who have received prior therapy including an anthracycline, a taxane and trastuzumab
- Metastatic hormone receptor-positive HER2-overexpressing breast cancer in postmenopausal women:
- PO 1500mg OD administered continuously in combination with PO letrozole 2.5mg OD
Tablet: 250mg
- Take at least 1 hour before or 1 hour after meals
Tyrosine Kinase Inhibitor
It inhibits intracellular tyrosine kinase domains of EGFR and HER2 receptors, promoting apoptosis
- Diarrhea
- Rash
- Nausea
- Vomiting
- Fatigue
- Hand-foot syndrome
- Headache
- Anorexia
- Alopecia
- Xeroderma
- Pruritus
- Asthenia
- Nail disorder
- Epistaxis
- Mucositis
- Extremity pain
- Arthralgia
- Dyspnea
- Dyspepsia
- Back pain
- Decreased left ventricular ejection fraction
- Photosensitivity
- Increased ALT/AST
- Increased bilirubin
- Hypersensitivity to components
- Breastfeeding during treatment and 1 week after discontinuation
WARNING:
- Severe hepatotoxicity reported days to months after treatment initiation
- Flibanserin
- Lefamulin
- Lomitapide
- Lonafarnib
- Pimozide
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Lapanix | 250mg | Tablet | 150’s | Beacon Medicare | Generics Africa |